Hemotune Secures CHF 14 Million for Clinical Trials

Hemotune sichert sich CHF 14 Millionen für klinische Studien

Di, Mrz 26. 2024

Hemotune’s innovative blood purification platform, HemoSystem, propels into clinical trials with a CHF 14 million Series B2 boost.

Hemotune AG, a Swiss biotech compmany, has concluded its Series B2 funding round, raising CHF 14 million, they claim in a press release. This pivotal financial injection, spearheaded by Belmondo and supported by stalwarts such as VP Venture Partners, heralds in the next stage of clinical trials for its groundbreaking HemoSystem blood purification platform.

The HemoSystem, uses nanoengineered magnetic beads. By eliminating large biomolecules directly from the bloodstream, it offers a novel avenue for multi-target treatments unattainable through conventional drug therapies.

Initially targeting the formidable challenge of sepsis-related immune suppression—a condition responsible for approximately 11 million fatalities annually and imposing a significant economic strain.

Lukas Langenegger, CEO and co-founder of Hemotune AG, expressed profound pride in the team’s milestone achievement of preclinical development and clinical trials.

Dr. Darius Madjdpour, the visionary founder at Belmondo, lauded Hemotune’s stellar performance over the past seven years, culminating in a platform technology with unparalleled potential in the medical field.

The HemoSystem’s capacity to address a spectrum of diseases and enable novel therapies was a key motivator for Belmondo’s lead role in this funding round.

Pascal Winnen, CEO of HEMEX, reaffirmed the CRO’s dedication to supporting Hemotune’s novel strategy to combat septic shock, recognising the technology’s vast potential to filter detrimental agents from the bloodstream selectively.

Verwandte Geschichten

Schweizer FDI steigen an: Während Auslandsinvestitionen in Deutschland zurückgehen

2 Mai 2024

Inmitten eines allgemeinen Rückgangs der europäischen Auslandsinvestitionen sticht die Schweiz mit einem Anstieg der Projekte um über 50% und...

Credit Suisse CEO To Step Down As UBS Merger Accelerates

6 Mai 2024

UBS plans to dissolve Credit Suisse's management in the coming weeks, with CEO Ulrich Körner leaving post-merger,...

PSP Swiss Property: Strong Earnings

7 Mai 2024

PSP Swiss Property boosts 2024 earnings, with Q1 net profits up 42% to CHF 81 million. Revised EBITDA forecast now at...

Bern Riots: 11 Policeman Injured & Arrests

6 Mai 2024

Unrest at Bern's Schützenmatte results in serious accusations by the regional police chief against rioters. ...

Swiss Firm, Montana Aerospace: 2024 Q1 Performance

8 Mai 2024

Montana Aerospace AG reports a stellar Q1 2024 with solid financial growth and reconfirmed future guidance....

Garrett Motion $800 Million Notes After Bad Q1

8 Mai 2024

Garrett Motion Inc. elevates its offering to $800 million in senior unsecured notes, with a proactive response to its...

Hochdorf: Shareholders To Change The Board

3 Mai 2024

Hochdorf faces a significant board transformation as Newlat proposes six new candidates, predominantly Italian....

In Kontakt bleiben

Erwähnenswert

The Federal Council Want to Invest €5Bn in Ukraine

Erwähnenswert

10. April 2024

Der Bundesrat will 5 Mrd. € in der Ukraine investieren

Erwähnenswert

5 Mai 2024

Hemotune sichert sich CHF 14 Millionen für klinische Studien

Hemotune sichert sich CHF 14 Millionen für klinische Studien

Verwandte Geschichten

In Kontakt bleiben

Erwähnenswert

Der Bundesrat will 5 Mrd. € in der Ukraine investieren

Sunday 5th: Today’s Headlines & Reports

Schnelle Links